Stock Analysis

Nanexa Second Quarter 2024 Earnings: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

OM:NANEXA
Source: Shutterstock

Nanexa (STO:NANEXA) Second Quarter 2024 Results

Key Financial Results

  • Revenue: kr10.8m (down 37% from 2Q 2023).
  • Net loss: kr6.01m (loss narrowed by 40% from 2Q 2023).
  • kr0.04 loss per share (improved from kr0.16 loss in 2Q 2023).
earnings-and-revenue-growth
OM:NANEXA Earnings and Revenue Growth August 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nanexa Earnings Insights

Looking ahead, revenue is expected to decline by 64% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Sweden are expected to grow by 18%.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 5.2% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Nanexa has 5 warning signs (and 2 which are a bit unpleasant) we think you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Nanexa might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.